MCE 国际站:Hydroxysafflor yellow A
参考详情:Hydroxysafflor yellow A (Safflomin A,羟基红花黄色素A) - 仅供科研 | 抗癌剂 | MCE
中文名:羟基红花黄色素A
CAS:78281-02-4
品牌:MedChemExpress (MCE)
存储条件:4°C, protect from light
生物活性:羟基红花黄 A 是从中药红花中分离得到的黄酮类化合物,具有抗肿瘤活性。 IC50 值: 靶标:体外:HYSA 可抑制 LPS 诱导的 VSMCs 增殖和迁移,同时下调几种关键促炎细胞因子的水平,包括 TNF-α、IL-6 和 IL-8。我们进一步表明,HYSA 可抑制 LPS 诱导的 TLR-4 表达上调以及 Rac1/Akt 通路的激活 [1]。 HSYA 保护 EC 活力免受 LPS 诱导的损伤 (P<0.05)。 LPS 诱导的 NF-κB p65 亚基 DNA 结合 (P<0.01) 和 B 细胞抑制剂-α (I-κB-α) 磷酸化中的 kappa 轻多肽基因增强子核因子被 HSYA 抑制。 HSYA 减弱的 LPS 触发 ICAM-1 和 E-选择素 mRNA 水平升高和 p38 MAPK 或 c-Jun N-末端激酶 MAPK 的磷酸化 [2]。 HSYA 抑制 3T3-L1 前脂肪细胞的增殖,细胞活力以剂量和时间依赖性方式大大降低。 HSYA (1 mg/l) 显着降低脂肪细胞中的细胞内脂质和甘油三酯含量 21.3 %(2.13 ± 0.36 对比 2.71 ± 0.40,P < 0.01)和 22.6 %(1.33 ± 0.07 对比 1.72 ± 0.07,P < 0.01) )分别在分化后第 8 天 [3]。体内:HSYA 治疗通过降低大鼠丙氨酸氨基转移酶 (ALT)、天冬氨酸氨基转移酶 (AST)、透明质酸 (HA)、层粘连蛋白 (LN) 和 III 型前胶原 (III-C) 的水平来改善血清生化指标 [4] .
体外:Hydroxysafflor yellow A (10 μM, 24 h) 通过 toll 样受体 -4 途径抑制脂多糖诱导的血管平滑肌细胞的增殖和迁移[1]。 Hydroxysafflor yellow A (0.01-10 mg/L, 4-96 h) 通过提高 HSL 启动子活性来促进脂溶特异性酶 HSL 的表达来抑制 3T3-L1 前脂肪细胞的增殖和脂肪形成[2]。 Hydroxysafflor yellow A (1-100 μM, 12-24 h) 通过抑制 p38 MAPK 磷酸化、 NF-κB活化、炎症因子高表达和白细胞对 EC 的粘附降低 LPS 诱导的 EC 炎症损伤[3]。 Hydroxysafflor yellow A (20-160 μM, 24-48 h) 通过阻断肝癌细胞自噬通量抑制细胞增殖和促进细胞凋亡[6]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only.
体内:Hydroxysafflor yellow A (2.5 或 10 mg/kg/day, 腹腔注射, 连续 6 周) 通过增强肝组织抗氧化能力、抑制 TGF-β1 表达保护大鼠肝脏免受长期酒精损伤[4]。 Hydroxysafflor yellow A (30, 48, 76.8 mg/kg, 腹腔注射) 通过减弱 NF-κB 和 p38MAPK 信号转导对慢性阻塞性肺疾病大鼠炎性损伤具有保护作用[5]。 Hydroxysafflor yellow A (1.135, 2.25 mg/kg 腹腔注射) 在裸鼠肿瘤模型中可抑制肿瘤生长,阻断肝癌细胞自噬[6]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Liver injury model induced by alcohol[4] Dosage: 2.5 or 10 mg/kg Administration: i.p. daily for 6 weeks Result: Decreased the level of ALT and AST. Decreased the levels of HA, LN, and III-C. Increased the activities of SOD and GPx and decreased the level of TGF-β1 expression. Animal Model: Chronic obstructive pulmonary disease (COPD)[5] Dosage: 30, 48, 76.8 mg/kg Administration: i.p. Result: Inhibited the elevated IL-6, IL-1β, TNF-α, ICAM-1 and VCAM-1 mRNA Levels. Inhibited the increased phosphorylation and NF-κB p65 levels.
热销产品:Montelukast | λ-Carrageenan | Isoorientin | Clomiphene (citrate) | 3-Hydroxyphenylacetic acid | Nifuroxazide | Linopirdine | Ipratropium (bromide) | ML148 | Quinidine hydrochloride monohydrate
研究领域:Others | Apoptosis | Autophagy
作用靶点:Others | Apoptosis | Autophagy
Trending products:Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Fluorescent Dye | PROTAC | Isotope-Labeled Compounds | Oligonucleotides
参考文献:
[1]. Yang G, et al. Hydroxysafflor yellow A inhibits lipopolysaccharide-induced proliferation and migration of vascular smooth muscle cells via Toll-like receptor-4 pathway. Int J Clin Exp Med. 2015 Apr 15;8(4):5295-302.[2]. Zhu HJ, et al. Hydroxysafflor yellow A (HYSA) inhibited the proliferation and differentiation of 3T3-L1 preadipocytes. Cytotechnology. 2015 Oct;67(5):885-92.[3]. Jin M, et al. Hydroxysafflor yellow A attenuate lipopolysaccharide-induced endothelium inflammatory injury. Chin J Integr Med. 2016 Jan;22(1):36-41.[4]. He Y, et al. Protective effects of hydroxysafflor yellow A (HSYA) on alcohol-induced liver injury in rats. J Physiol Biochem. 2015 Mar;71(1):69-78.[5]. Jin M, Xue et al. Protective Effect of Hydroxysafflor Yellow A on Inflammatory Injury in Chronic Obstructive Pulmonary Disease Rats. Chin J Integr Med. 2019 Oct;25(10):750-756.[6]. Wu N, et al. Hydroxysafflor yellow A promotes apoptosis via blocking autophagic flux in liver cancer. Biomed Pharmacother. 2021 Apr;136:111227.